001), platelets (P < 0.001) and stiffness (P < 0.001) were independently associated with CSPH. CP868596 When categorizing patients according to vWF-Ag levels below or above 241%, OR for the presence of CSPH was 4.17 (P = 0.017; corrected for liver stiffness and platelet count). Using Liver stiffness measured by TE for the diagnosis of CSPH resulted in an AUC of 0.907 (CI: 0.855-0.960) and in an AUC

of 0.886 (CI: 0.829-0.943) for the diagnosis of severe PH in compensated cirrhosis (Table 2). Comparing the AUC in patients with valid TE measurement and vWF-Ag, there was no significant difference in the AUCs (P = 0.08). Because TE was unsuccessful in 41 of 128 of compensated patients (mainly because of obesity), we calculated ROC curves with the ITD approach. AUC-ITD for TE—including all patients regardless of success of TE—was 0.79 (CI: 0.71-0.86). Erlotinib datasheet To compare the predictive power of TE and vWF-Ag for noninvasive diagnosis of CSPH and severe PH, a comparison of AUCs (AUC-ITD for TE and AUC for vWF-Ag) was computed, resulting in a similar performance of vWF-Ag if the unsuccessful cases of TE were included (P = 0.135). The median follow-up

time was 33 months (95% CI: 30-36 months). Overall, 91 patients died during follow-up. Overall median transplant-free survival time was 59 months. Median vWF-Ag was significantly higher in patients who died during follow-up period, compared to patients who were still alive at the end of follow-up (387% [IQR 288%-457%] versus 271% [IQR 200%-358%]; P < 0.0001). The adjusted HR for mortality was 4.1% per increase of vWF-Ag MCE公司 of 10% points. At a cutoff of vWF-Ag of 315% for mortality, the HR was

3.37 (95% CI: 2.21-5.15). This cutoff also predicted mortality (HR: 2.92; 95% CI: 1.72-4.97) (P < 0.001) independently of CPS, MELD, HCC, and HVPG in multivariate analysis. In patients without HCC (n = 235), the HR ratio (univariate) for mortality in case of vWF-Ag >315% was 4.42 (95% CI: 2.5-7.7; P < 0.001), whereas in multivariate analysis, considering CPS, MELD, HVPG, and vWF-Ag >315% as a categorical variable, the HR was 3.49 (95% CI: 1.8-6.6; P < 0.001). vWF-Ag equals MELD in mortality prediction (AUC = 0.71 [95% CI: 0.65-0.77] versus AUC = 0.65 [95% CI: 0.58-0.72]; P = 0.197) (Fig. 4). Considering only patients with CSPH, AUC of vWF-Ag was not significantly different, compared to MELD (0.690 [95% CI: 0.618-0.763] versus 0.620 [95% CI: 0.540-0.699]; P = 0.222). Twenty-five percent mortality level was reached after 53 months if the baseline vWF-Ag was <315%, compared to 9 months in patients with vWF-Ag >315% (P < 0.001) (Fig. 5A–C). Compensated patients had 25% mortality after 53 months if the baseline vWF-Ag was <315%, compared to 15 months in patients with vWF-Ag >315% (P < 0.001). Decompensated patients had a mortality of 25% after 37 and 7 months if their vWF Ag was <315% and if vWF-Ag was >315%, respectively (P = 0.002).